In recent years, we have witnessed prominent improvements in urinary catheter coatings to tackle the commonly occurring catheter-associated urinary tract infection (CAUTI) in catheterized patients. CAUTIs are claimed to be one of the most frequent nosocomial infections that can lead to various complications, from catheter encrustation to severe septicaemia and pyelonephritis. Besides general prevention hygienic strategies, antimicrobial-coated urinary catheters show great potential in the prevention of urinary catheter-associated complications. The aim of this review is to present and evaluate recent updates on the development of antimicrobial urinary catheters in the context of the aetiology of urinary malfunction. Subsequently, we shed some light on future perspectives of utilizing 3D printing and the surrounding regulatory directions.
The vast scope of 3D printing has ignited the production of tailored medical device (MD) development and catalyzed a paradigm shift in the health-care industry, particularly following the COVID pandemic. This review aims to provide an update on the current progress and emerging opportunities for additive manufacturing following the introduction of the new medical device regulation (MDR) within the EU. The advent of early-phase implementation of the Quality by Design (QbD) quality management framework in MD development is a focal point. The application of a regulatory supported QbD concept will ensure successful MD development, as well as pointing out the current challenges of 3D bioprinting. Utilizing a QbD scientific and risk-management approach ensures the acceleration of MD development in a more targeted way by building in all stakeholders’ expectations, namely those of the patients, the biomedical industry, and regulatory bodies.
21 July 2022 in Journal of Pharmaceutical Sciences
Cosmetics, for a long period of time have been used as beauty products for the care of body and face which eventually enhances a person’s appearance. These products are usually constituted from a mixture of different chemical compounds which are synthetic as well as organic in nature. For a long period of time, these products have not come under the ambit of regulatory authorities and have gone through the markets unchecked. The way a drug manufacturing and sale process is monitored by the regulatory authorities across the world, which includes careful monitoring of clinical trials, scrutinizing research results like safety, efficacy and quality of a drug has been avoided for a long period of time in case of parameters related to cosmetics. Some groups alleged that the industry practices are flawed, that there is little government regulation, and that cosmetics contain cancer-causing chemicals and other toxicants which are harmful for human body. Rules have certainly changed over time and major countries like India have started following guidelines while giving regulatory approval to cosmetics just like USA. The U.S. (FDA) functions include the banning and restriction of ingredients for safety purposes. The Cosmetic Ingredient Review (CIR) which is an independent review board that critically evaluates chemical ingredients used in cosmetics and publishes results of its findings. Similarly in India, CDSCO (Central Drugs Standard Control Organisation) and DCGI (Drug Controller General Of India), both are responsible for evaluating the composition of cosmetic products and their safety while referring to a drafted set of guidelines known as BIS( Bureau of Indian standards) guidelines. The article focuses on various aspects considered by USA and India while giving regulatory approval to cosmetic products.
Intravascular catheter-associated infections pose a significant threat to the health of patients because of biofilm formation. Hence, it is imperative to exploit cost-effective approaches to improve patient compliance. With this aim, our present study reported the potential of an antimicrobial polymeric gel coating of chitosan (CS) and chlorhexidine (CHX) on the marketed urinary catheters to minimize the risk of biofilm formation. The study involved the implementation of the Quality by Design (QbD) approach by identifying the critical parameters that can affect the coating of the catheter’s surface in any possible way. Later, design of experiments (DoE) analysis affirmed the lack of linearity in the model for the studied responses in a holistic manner. Moreover, in vitro studies were conducted for the evaluation of various parameters followed by the antibiofilm study. The coating exhibited promising release of CHX in the artificial urinary media together with retention of the coating on the catheter’s surface. Therefore, this study aims to emphasize the importance of a systematic and quality-focused approach by contributing to the development of a safe, effective, and reliable catheter coating to enhance intravascular catheter safety.
15 December 2020 in International Journal of Drug Regulatory Affairs
Good Manufacturing Practice (GMP) is set of guidelines enforced by USFDA under 21 CFR. Every Manufacturer of Food, Cosmetics, Pharmaceuticals products, Medical Devices & Dietary products should follow these guidelines in order to be sure that their product is safe and effective to be put in the market and for use by general population. The parameters of GMP for different Categories may vary but there is only one aim & that is to prevent any kind of harm that can occur to the final user of the product.